Ergoteles’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Ergoteles’s Portfolio IBER.U Stock Details IBER.U Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13,850	Closed	-$137K	–	2087
2022 Q3	$137K	Hold	13,850	–	–	﹤0.01%	1299
2022 Q2	$136K	Hold	13,850	–	–	﹤0.01%	1443
2022 Q1	$137K	Hold	13,850	–	–	0.01%	1069
2021 Q4	$139K	Hold	13,850	–	–	0.01%	1106
2021 Q3	$138K	Hold	13,850	–	–	0.01%	1066
2021 Q2	$139K	Hold	13,850	–	–	﹤0.01%	1355
2021 Q1	$137K	Buy	+13,850	New	+$138K	﹤0.01%	714

Other funds holding IBER.U

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return

TAM

Terrapin Asset Management Miami, Florida $87.8M AUM 16.84% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ergoteles's IBER.U Position: Q4 2022 in Review

Ergoteles sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q4 2022, closing a stake of 13,850 shares — an estimated $137K sold.

Ergoteles first reported a position in IBER.U in Q1 2021 and held it in 7 quarters. The position peaked at $139K in Q4 2021. 10 funds tracked by Wall St. Rank hold IBER.U as of Q4 2022.

Ergoteles reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 13,850 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q4 2022, an estimated $137K.
Ergoteles first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 7 quarters.
Ergoteles's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $139K in Q4 2021.
10 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.